Related Experiment Video
Updated: Nov 23, 2025
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and
Brenna D Appleton1, Amy S Major2,3
1Department of Pathology, Microbiology and Immunology, Vanderbilt University.
Insights
Systemic lupus erythematosus (SLE) accelerates atherosclerosis through chronic inflammation, not just traditional risk factors. SLE treatments may also reduce atherosclerosis by targeting inflammation and improving cardiovascular health.
Area of Science:
- Cardiovascular Medicine
- Rheumatology
- Immunology
Background:
- Accelerated atherosclerosis is a major cause of death in systemic lupus erythematosus (SLE) patients.
- SLE-accelerated atherosclerosis involves complex mechanisms beyond traditional cardiovascular risk factors.
- Understanding these mechanisms is crucial for improving patient outcomes.
Purpose of the Study:
- To review current understanding of SLE-accelerated atherosclerosis.
- To summarize new insights into evaluation, treatment, and mechanisms.
- To highlight the interplay between SLE, inflammation, and cardiovascular disease.
Main Methods:
- Review of recent scientific literature on SLE and atherosclerosis.
- Analysis of inflammatory biomarkers in cardiovascular risk assessment for SLE patients.
- Examination of the impact of SLE therapeutics on atherosclerosis development.
Main Results:
- Inflammatory biomarkers are essential for CVD risk assessment in SLE.
- SLE therapeutics can hinder atherosclerosis by reducing inflammation and directly improving cardiovascular measures.
- SLE disease activity management is critical for controlling atherosclerosis.
Conclusions:
- SLE-accelerated atherosclerosis is primarily driven by chronic autoimmune inflammation.
- Integrated management of SLE activity and cardiovascular risk factors is necessary.
- Further research into underlying mechanisms will enable targeted therapies and better outcomes for SLE patients.
Purpose Of Review:
Accelerated atherosclerosis is a significant comorbidity and the leading cause of death for patients with systemic lupus erythematosus (SLE). It is now apparent that SLE-accelerated atherosclerosis is not driven solely by traditional cardiovascular risk factors, adding complexity to disease characterization and mechanistic understanding. In this review, we will summarize new insights into SLE-accelerated atherosclerosis evaluation, treatment, and mechanism.
Recent Findings:
Recent work highlights the need to incorporate inflammatory biomarkers into cardiovascular disease (CVD) risk assessments. This is especially true for SLE patients, in which mechanisms of immune dysfunction likely drive CVD progression. There is new evidence that commonly prescribed SLE therapeutics hinder atherosclerosis development. This effect is achieved both by reducing SLE-associated inflammation and by directly improving measures of atherosclerosis, emphasizing the interconnected mechanisms of the two conditions.
Summary:
SLE-accelerated atherosclerosis is most likely the consequence of chronic autoimmune inflammation. Therefore, diligent management of atherosclerosis requires assessment of SLE disease activity as well as traditional cardiovascular risk factors. This supports why many of the therapeutics classically used to control SLE also modulate atherosclerosis development. Greater understanding of the mechanisms underlying this condition will allow for the development of more targeted therapeutics and improved outcomes for SLE patients.
Related Concept Videos
01:26Atherosclerosis III: Management
01:30Atherosclerosis I: Introduction
01:23Atherosclerosis IV: Nursing Management
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology